1. Home
  2. PDI vs DFTX Comparison

PDI vs DFTX Comparison

Compare PDI & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PIMCO Dynamic Income Fund

PDI

PIMCO Dynamic Income Fund

HOLD

Current Price

$14.15

Market Cap

7.1B

Sector

Finance

ML Signal

HOLD

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

HOLD

Current Price

$33.26

Market Cap

5.9B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDI
DFTX
Founded
N/A
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
7.1B
5.9B
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
PDI
DFTX
Price
$14.15
$33.26
Analyst Decision
Strong Buy
Analyst Count
0
19
Target Price
N/A
★ $72.33
AVG Volume (30 Days)
★ 4.1M
2.0M
Earning Date
01-01-0001
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.73
$14.62
52 Week High
$19.00
$49.70

Technical Indicators

Market Signals
Indicator
PDI
DFTX
Relative Strength Index (RSI) 42.27 37.40
Support Level N/A $32.84
Resistance Level $14.56 $38.04
Average True Range (ATR) 0.21 1.55
MACD 0.04 -0.23
Stochastic Oscillator 23.16 15.38

Price Performance

Historical Comparison
PDI
DFTX

About PDI PIMCO Dynamic Income Fund

PIMCO Dynamic Income Fund is a United States-based closed-end management investment company. The fund's investment objective is to seek current income. Its secondary objective is to seek capital appreciation. The fund invests world-wide in a portfolio of debt obligations and other income-producing securities with varying maturities and related derivative instruments. Its investment portfolio includes mortgage-backed securities, investment-grade, and high-yield corporates, corporate and sovereign bonds, other income-producing securities, and related derivative instruments.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: